GSK (GSK) to Release Earnings on Wednesday

GSK (NYSE:GSK - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, July 30th. Analysts expect GSK to post earnings of $1.12 per share and revenue of $7.92 billion for the quarter. GSK has set its FY 2025 guidance at 4.250-4.590 EPS.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.82% and a net margin of 9.89%. The business's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.43 EPS. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

GSK Trading Down 0.7%

GSK traded down $0.28 during midday trading on Friday, hitting $37.95. 4,009,306 shares of the company were exchanged, compared to its average volume of 5,818,628. The firm has a market capitalization of $77.70 billion, a P/E ratio of 19.56, a P/E/G ratio of 1.56 and a beta of 0.50. GSK has a 1-year low of $31.72 and a 1-year high of $44.67. The firm's 50 day moving average price is $39.03 and its 200-day moving average price is $37.50. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, July 10th. Stockholders of record on Friday, May 16th were paid a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.44%. This is an increase from GSK's previous quarterly dividend of $0.39. The ex-dividend date was Friday, May 16th. GSK's payout ratio is currently 88.14%.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of recent analyst reports. Wall Street Zen downgraded GSK from a "buy" rating to a "hold" rating in a research note on Saturday. Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Hsbc Global Res raised GSK to a "strong sell" rating in a research note on Monday, April 28th. Finally, BNP Paribas initiated coverage on GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, GSK currently has a consensus rating of "Hold" and an average price target of $37.38.

Hedge Funds Weigh In On GSK

Several institutional investors have recently modified their holdings of GSK. Brighton Jones LLC purchased a new stake in shares of GSK during the fourth quarter worth $528,000. AQR Capital Management LLC increased its holdings in shares of GSK by 84.4% in the first quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company's stock worth $1,559,000 after buying an additional 18,420 shares during the period. Finally, Empowered Funds LLC increased its holdings in shares of GSK by 2.1% in the first quarter. Empowered Funds LLC now owns 79,174 shares of the pharmaceutical company's stock worth $3,067,000 after buying an additional 1,598 shares during the period. 15.74% of the stock is owned by institutional investors.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.